Alphyn is creating and leading the new class of drugs
Alphyn Biologics, Inc. (Alphyn) is creating and leading the new class of drugs known as Multi-target Therapeutics, leveraging its unique, patent-pending AB-101 platform biomaterial to develop improved therapies for diseases, in particular for those with poor or no treatment options. Alphyn’s AB-101 has over 40 bio-active compounds to target and cure diseases. AB-101, as a result of its many bioactive compounds, targets multiple diseases, and, has multiple ways to attack each disease providing Alphyn a rich and deep product pipeline.
AB-101 first product, EC1 to treat Atopic Dermatitis, solves one of the largest medical challenges to humankind – Atopic Dermatitis, including drug resistant infections. EC1 is actively moving to the Phase 2 clinical trial.
Alphyn’s management team, boards and commercial partners are highly experienced and successful in life science early stage and large companies.
Alphyn’s AB-101 started with Dr. Pekoe’s work as team lead for the development and FDA approval of Bactroban® (generic name mupirocin). In the years following, Dr Pekoe continued his interest and research in skin diseases. It was in this work that Dr. Pekoe identified and began testing AB-101, finally bringing a team together to create Alphyn Biologics for development of a new class of drugs, Multi-target Therapeutics, using AB-101 to create powerful new drugs for disease with no or less than optimal treatments.